

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8209616

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	CITIBANK, N.A.	10/06/2023
RECEIVING PARTY DATA		
Name:	HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)	
Street Address:	1 HORIZON WAY	
City:	DEERFIELD	
State/Country:	ILLINOIS	
Postal Code:	60015	
Name:	HZNP LIMITED	
Street Address:	70 ST. STEPHEN'S GREEN	
City:	DUBLIN 2	
State/Country:	IRELAND	
Postal Code:	D02 E2X4	
Name:	HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)	
Street Address:	1 HORIZON WAY	
City:	DEERFIELD	
State/Country:	ILLINOIS	
Postal Code:	60015	
PROPERTY NUMBERS Total: 30		
Property Type	Number	
Patent Number:	9926537	
Application Number:	15649478	
Application Number:	15356046	
Application Number:	15906839	
Application Number:	15679401	
Application Number:	15216585	
Patent Number:	9504699	
Patent Number:	8920838	
Application Number:	15316049	

Property Type	Number
Application Number:	15238149
Patent Number:	10045958
Patent Number:	9326966
Patent Number:	9962358
Patent Number:	9999608
Application Number:	15980376
Application Number:	15402780
Application Number:	15687136
Application Number:	15687141
Patent Number:	9914692
Application Number:	15696448
Application Number:	15684876
Patent Number:	10045959
Patent Number:	9962359
Patent Number:	9254278
Application Number:	15944411
Application Number:	15944428
Application Number:	15944422
Application Number:	15639171
Application Number:	15687144
Application Number:	15699188

CORRESPONDENCE DATA

Fax Number: (212)291-9868

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (212) 558-4229

Email: demarcor@sullcrom.com, nguyenb@sullcrom.com

Correspondent Name: RAFFAELE A. DEMARCO

Address Line 1: 125 BROAD STREET

Address Line 2: SULLIVAN & CROMWELL LLP

Address Line 4: NEW YORK, NEW YORK 60015

ATTORNEY DOCKET NUMBER: 019095.00083 (RAD)

NAME OF SUBMITTER: RAFFAELE A. DEMARCO

SIGNATURE: /Raffaele A. DeMarco/

DATE SIGNED: 10/06/2023

Total Attachments: 5

source=Horizon- Patent Release (October 2018 PSA) (Agreed Form)#page1.tif

source=Horizon- Patent Release (October 2018 PSA) (Agreed Form)#page2.tif

source=Horizon- Patent Release (October 2018 PSA) (Agreed Form)#page3.tif

source=Horizon- Patent Release (October 2018 PSA) (Agreed Form)#page4.tif

source=Horizon- Patent Release (October 2018 PSA) (Agreed Form)#page5.tif

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of October 6, 2023 (the “Effective Date”), is made by Citibank, N.A., in its capacity as Administrative Agent and Collateral Agent (the “Agent”), in favor of the grantor parties identified on the signature page hereto (the “Grantors”).

WHEREAS, pursuant to that certain U.S. Pledge and Security Agreement, dated as of May 7, 2015, by and among the Agent, the Grantors and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the “Security Agreement”), the Grantors granted to the Agent, in its capacity as Administrative Agent and Collateral Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantors executed and delivered a Patent Security Agreement, dated as of October 23, 2018 (the “October 2018 Patent Security Agreement”), for recordal with the United States Patent and Trademark Office;

WHEREAS, the October 2018 Patent Security Agreement was recorded with the United States Patent and Trademark Office on October 24, 2018 at Reel/Frame 047720/0068.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the October 2018 Patent Security Agreement, as applicable.
2. Release. The Agent, without representation or warranty of any kind, hereby irrevocably releases, discharges, terminates and cancels all of its security interest in all of the Grantors’ right, title and interest, wherever located, in and to: (i) any and all patents and patent applications that were granted in connection with the October 2018 Patent Security Agreement, including those listed on Schedule 1 hereto; (ii) all inventions and improvements described and claimed therein; (iii) all reissues, divisions, continuations, renewals, extensions, and continuations-in-part thereof; (iv) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (v) all rights to sue for past, present, and future infringements thereof; and (vi) all rights corresponding to any of the foregoing throughout the world.
3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the October 2018 Patent Security Agreement.
4. Recordation. The Agent hereby authorizes and requests that the Commissioner for Patents of the United States Patent and Trademark Office record this Release.
5. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantors and their successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantors, at the Grantors’ sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

6. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

[Signature Page Follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

CITIBANK, N.A., acting in its capacity as
Administrative Agent and Collateral Agent

By: Kevin Q. Ciolek

Name: Kevin Ciolek

Title: Vice President

GRANTORS:

**HORIZON THERAPEUTICS USA,
INC.**

HZNP LIMITED

HORIZON THERAPEUTICS, LLC

SCHEDULE 1

PATENTS

	Owner	Patent Title	Serial No. Filing Date	Patent No. Issue Date
1.	Horizon Pharma Rheumatology LLC	Variant forms of urate oxidase and use thereof	15649462 07/13/2017	9926537 03/27/2018
2.	Horizon Pharma Rheumatology LLC	Variant forms of urate oxidase and use thereof	15649478 07/13/2017	
3.	Horizon Pharma Rheumatology LLC	Purification of proteins with cationic surfactant	15356046 11/18/2016	
4.	Horizon Pharma Rheumatology LLC	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy	15906839 02/27/2018	
5.	Horizon Pharma Rheumatology LLC (Applicant)	Aggregate-free urate oxidase for preparation of non- immunogenic polymer conjugates	15679401 08/17/2017	
6.	HZNP Limited and The American Oncological d/b/a Hospital of the Fox Chase Cancer Center	Combination of immunomodulatory agent with pd-1 or pd-11 checkpoint inhibitors in the treatment of cancer	15216585 07/21/2016	
7.	HZNP Limited	Delayed-release glucocorticoid treatment of rheumatoid disease	14563000 12/08/2014	9504699 11/29/2016
8.	HZNP Limited	Delayed-release glucocorticoid treatment of rheumatoid disease	13860015 04/10/2013	8920838 12/30/2014
9.	Horizon Therapeutics, LLC	Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels	15316049 12/02/2016	
10.	Horizon Therapeutics, LLC	Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy	15238149 08/16/2016	
11.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15944398 04/03/2018	10045958 08/14/2018
12.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	14958259 12/03/2015	9326966 05/03/2016
13.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15687118 08/25/2017	9962358 05/08/2018
14.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15457643 03/13/2017	9999608 06/19/2018
15.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15980376 05/15/2018	
16.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of phenylacetic acid prodrugs	15402780 01/10/2017	
17.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of phenylacetic acid prodrugs	15687136 08/25/2017	
18.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of phenylacetic acid prodrugs	15402780 01/10/2017	
19.	Horizon Therapeutics, LLC	Methods of treating urea cycle disorders	15687141 08/25/2017	
20.	Horizon Therapeutics, LLC	Procedure for the preparation of 4-phenyl butyrate and uses thereof	15164126 05/25/2016	9914692 03/13/2018

	Owner	Patent Title	Serial No. Filing Date	Patent No. Issue Date
21.	Horizon Therapeutics, LLC	Procedure for the preparation of 4-phenyl butyrate and uses thereof	15696448 09/06/2017	
22.	Horizon Therapeutics, LLC	Treatment of urea cycle disorders in neonates and infants	15684876 08/23/2017	
23.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15944416 04/03/2018	10045959 08/14/2018
24.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15687132 08/25/2017	9962359 05/08/2018
25.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	14816674 08/03/2015	9254278 02/09/2016
26.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15944411 04/03/2018	
27.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15944428 04/03/2018	
28.	Horizon Therapeutics, LLC	Methods of therapeutic monitoring of nitrogen scavenging drugs	15944422 04/03/2018	
29.	Horizon Therapeutics, LLC (Applicant)	Methods of treating urea cycle disorders	15639171 06/30/2017	
30.	Horizon Therapeutics, LLC	Methods of treating urea cycle disorders	15687144 08/25/2017	
31.	Horizon Therapeutics, LLC	Methods of treating urea cycle disorders	15699188 09/08/2017	